Biocon informs about disclosure

Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Announces U.S. FDA Approval for Yesintek® (ustekinumab-kfce) Single-dose Prefilled Autoinjector’. The above information will also be available on the website of the Company at www.biocon.com

The above information is a part of company’s filings submitted to BSE.